MedTrace Logo

Role of Inflammatory Markers in Sepsis

NCT06111963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-07-16

No results posted yet for this study

Summary

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Conditions

  • Diagnostic

Interventions

DIAGNOSTIC_TEST

Serology tests

CD4, CD25, IL17

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Walaa Y Elsabeeny, MD · National Cancer Institute, Cairo University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-01-05
Completion
2025-01-25

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06111963 on ClinicalTrials.gov